Immune-mediated complications during interferon therapy in hematological patients

Acta Haematologica

Volumn 107, Issue 3, 2002, Pages 133-144

  Raanani, Pia ^a,b   Ben Bassat, Isaac ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Connective tissue; Dermatological side effects; Hematological malignancy; Immune mediated complications; Interferon; Kidney; Thyroid

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; NIFEDIPINE; RECOMBINANT INTERFERON; THYROID ANTIBODY; TUMOR NECROSIS FACTOR;

ANTIBODY TITER; ARTHRITIS; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE HEPATITIS; AUTOIMMUNITY; BEHCET DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLITIS; CRYOGLOBULINEMIA; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG INDUCED DISEASE; FLU LIKE SYNDROME; HASHIMOTO DISEASE; HUMAN; HYPOTHYROIDISM; KIDNEY DISEASE; MYASTHENIA GRAVIS; MYELOPROLIFERATIVE DISORDER; NEUTROPHIL; PRIORITY JOURNAL; PROTEINURIA; PSORIASIS; RAYNAUD PHENOMENON; REVIEW; RISK FACTOR; SARCOIDOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; VITILIGO;

AUTOIMMUNE DISEASES; CONNECTIVE TISSUE DISEASES; HEMATOLOGIC DISEASES; HEMATOLOGIC NEOPLASMS; HUMANS; INTERFERONS; KIDNEY DISEASES; THYROID DISEASES;

EID: 0036236110     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000057631     Document Type: Review

References (77)

1. Interferon therapy in cancer: From imaginon to interferon
2. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia
3. Clinical toxicity of interferons in cancer patients: A review
4. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy
5. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors
6. Hypothyroidism and arthritis during interferon therapy
7. Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha
8. Development of autoimmune thyroid diseases during long-term treatment of hematological malignancies with alpha-interferons
9. Autoimmune thyroid dysfunctions in hematologic malignancies treated with alpha-interferon
10. Occurrence of primary hypothyroidism in alpha-interferon treatment
11. Interferon-alpha induced thyroid dysfunction: Three clinical presentations and a review of the literature
12. The pathogenesis of autoimmune thyroid disease
13. Alpha-interferon and immune hemolytic anemia
14. Recombinant alfa-2b-interferon therapy in untreated, stages A and B chronic lymphocytic leukemia. A preliminary report
15. Autoimmune haemolytic anaemia associated with interferon alfa-2a in a patient with mycosis fungoides
16. Interferon therapy for agnogenic myeloid metaplasia complicated by immune hemolytic anemia
17. Autoimmune hemolytic anemia induced by alpha-interferon therapy in a case of IgG-kappa type multiple myeloma
18. Severe intravascular hemolysis associated with interferon treatment for chronic myeloid leukemia
19. Autoimmune hemolytic anemia during alpha interferon treatment in nine patients with hematological diseases
20. Immune thrombocytopenia following alpha-interferon therapy in patients with cancer
21. Autoimmune mediated thrombocytopenia associated with the use of interferon-alpha in chronic myeloid leukemia
22. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura
23. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome
24. Hairy cell leukemia in association with thrombotic thrombocytopenic purpura and factor VIII antibodies
25. Thrombotic thrombocytopenic purpura complicating chronic myelogenous leukemia treated with interferon-alpha. A report of two successfully treated patients
26. Thrombotic thrombocytopenic purpura during interferon alpha treatment for chronic myelogenous leukemia
27. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders
28. Alpha-interferon-induced arthritis: Clinical presentation treatment, and prevention
29. Interferon-alpha-associated polyarthritis. Possible induction of seropositive rheumatoid arthritis by interferon-alpha: Two case reports and review of the literature
30. Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia
31. 35-Year-old patient with chronic myelogenous leukemia developing systemic lupus erythematosus after alpha-interferon therapy
32. Serum levels of interferons in patients with systemic lupus erythematosus
33. Behçet's disease induced by interferon therapy for chronic myelogenous leukemia
34. Behçet's disease in patients with chronic myelogenous leukemia: Possible role of interferon-alpha treatment in the occurrence of Behçet's symptoms
35. Skin hyperreactivity of Behçet's patients (pathergy reaction) is also positive in interferon alpha-treated chronic myeloid leukaemia patients, indicating similarly altered neutrophil functions in both disorders
36. Raynaud's phenomenon and cryoglobulinaemia associated with the use of recombinant human alpha-interferon
37. The Raynaud phenomenon and interferon therapy
38. Microangiopathy in patients with chronic myelogenous leukemia treated with interferon
39. Acrocyanosis induced by interferon alpha(2a)
40. Digital vasculitis associated with interferon therapy
41. Severe Raynaud's syndrome associated with interferon therapy. A case history
42. Raynaud's phenomenon and digital necrosis induced by interferon-alpha
43. Interferon-induced vasospasm in chronic myeloid leukaemia
44. Membranoproliferative glomerulonephritis in a patient with hairy-cell leukemia treated with alpha-II interferon
45. Investigations on the subclinical and clinical nephrotoxicity of interferon alpha-2B in patients with myeloproliferative syndromes
46. Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy
47. Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte a interferon therapy for mycosis fungoides
48. Nephrotic syndrome during treatment with interferon
49. Alpha-2-interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: A phase I-II trial
50. Renal toxicity in long-term alpha-interferon treatment in a patient with myeloma
51. Acute and definitive renal failure in progressive multiple myeloma treated with recombinant interferon alpha-2a: Report of two patients
52. Acute renal failure during interferon treatment
53. Hemolytic-uremic syndrome during recombinant alpha-interferon treatment for hairy cell leukemia
54. Recombinant interferon alpha and hemolytic uremic syndrome: Cause or coincidence?
55. Renal thrombotic microangiopathy in patients with chronic myelogenous leukaemia treated with interferon-alpha 2b
56. Nephropathies caused by interferon alpha: A propos of 2 cases
57. Thrombotic microangiopathy associated with alpha-interferon therapy for chronic myelocytic leukemia
58. Thrombotic microangiopathy in a patient with chronic myelocytic leukaemia treated with alpha-interferon
59. Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: Coincidence or true side effect?
60. The kidney is the main site of interferon degradation
61. An ultrastructural study of the development of nephritis in mice treated with interferon in the neonatal period
62. Psoriasis with articular involvement induced by interferon alfa
63. De novo development of psoriatic plaques in patients receiving interferon alfa for treatment of erythrodermic cutaneous T-cell lymphoma
64. A case of fatal pemphigus vulgaris in association with beta interferon and interleukin-2 therapy
65. Treatment with alpha interferon associated with the development of paraneoplastic pemphigus
66. Sarcoidosis following beta-interferon therapy for multiple myeloma
67. Cutaneous sarcoidosis in a patient with Philadelphia-positive chronic myelogenous leukemia treated with interferon-alpha
68. Sarcoidosis induced by interferon therapy for chronic myelogenous leukaemia
69. Interferon-alpha therapy associated with the development of sarcoidosis
70. Myasthenia gravis during interferon alfa therapy
71. Myasthenia gravis induced by alpha-interferon therapy
72. Myasthenia gravis after interferon-alpha treatment
73. Severe autoimmune hepatitis in a chronic myeloid leukemia patient treated with interferon alpha and with complete genetic response
74. Interferon-alpha induced autoimmune hepatitis in a patient with Philadelphia chromosome-positive chronic myeloid leukemia with cytogenetically normal T lymphocytes
75. Ulcerative colitis in hairy cell leukemia. A case report
76. Development of cyroglobulinemia and polyneuropathy in a chronic myeloid leukemia patient during interferon-alpha treatment
77. Immune-mediated side-effects of cytokines in humans